Q3FY23 Quarterly Result Announced for Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals announced Q3FY23 results: Q3FY23 & 9MFY23: Net Sales for the quarter up 19% to Rs 1,509 crores. Net Profit for the quarter at Rs 122 crores. Net sales for 9MFY23 up 9% to Rs 4,246 crore. Net profit for 9MFY23 at Rs 189 crore. Operational Q3FY23: India Formulations Business grew at 12% to Rs 545 crore in the quarter reflecting performance better than the industry - both in Specialty and Acute segments. Alembic's specialty segment grew 14% compared to the industry specialty growth of 10% (as per IQVIA) International Business Q3FY23: US Generics grew 10% to Rs 432 crore in the quarter. Ex-US International Formulations grew 7% to Rs 206 crore in the quarter. 9 ANDA approvals received during the quarter; 178 Cumulative ANDA approvals. 4 ANDA filings during the quarter; Cumulative ANDA filings at 246 Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "The Company witnessed topline growth across all the verticals. In particular, the API business outperformed with a 65% growth during the quarter" Result PDF01-02-2023